Core Viewpoint - Charles River Laboratories (CRL) has experienced a decline in share price of approximately 6.8% since its last earnings report, underperforming the S&P 500 index [1][2]. Financial Performance - For Q4 2025, CRL reported adjusted earnings per share (EPS) of $2.39, a decrease of 10.2% year over year, but exceeding the Zacks Consensus Estimate by 2.51% [3]. - The company recorded a full-year 2025 EPS of $10.28, down 0.4% from the previous year, yet surpassing the Zacks Consensus Estimate by 0.6% [4]. - Total revenues for Q4 2025 were $994.2 million, beating the Zacks Consensus Estimate by 0.84%, but reflecting a 0.8% decline from the same quarter last year [5]. - Full-year 2025 revenues amounted to $4.02 billion, a decrease of 0.9% from the prior year, while also exceeding the Zacks Consensus Estimate by 0.2% [5]. Segment Performance - Revenues from the Research Models and Services (RMS) segment were $206.3 million, up 1% year over year, but down 0.9% organically [6]. - The Discovery and Safety Assessment (DSA) segment reported revenues of $591.6 million, down 2% year over year and 3.3% organically [7]. - Manufacturing Solutions generated revenues of $196.4 million, reflecting a 0.7% increase year over year, but a 2.1% decline organically [8]. Margin Analysis - Gross profit for Q4 was $414.4 million, an increase of 8.8% from the prior year, with a gross margin of 41.7%, up 368 basis points year over year [9]. - Selling, general, and administrative expenses rose by 0.2% year over year to $196.1 million, while adjusted operating profit increased by 17.8% to $218.3 million, leading to an adjusted operating margin expansion of 347 basis points to 22% [9]. Liquidity Position - At the end of Q4 2025, CRL had cash and cash equivalents of $213.8 million, up from $194.6 million at the end of 2024 [11]. - Cumulative net cash provided by operating activities was $737.6 million, compared to $734.6 million a year ago [11]. Future Guidance - For 2026, CRL expects total revenues to be flat to a growth of 1.5%, with the Zacks Consensus Estimate for 2025 revenues at $4.07 billion, indicating a 1.6% growth [12]. - Adjusted EPS for 2026 is projected to be in the range of $10.70 to $11.20, with the Zacks Consensus Estimate at $10.59 [12]. Estimate Trends - Recent estimates for CRL have trended downward, with a consensus estimate shift of -20.22% over the past month [13]. VGM Scores - CRL currently holds a subpar Growth Score of D and a similar score for momentum, but has a grade of B for value, placing it in the top 40% for value investors [14]. Overall Outlook - The overall trend for estimates has been downward, indicating a shift in expectations, with CRL holding a Zacks Rank of 3 (Hold), suggesting an in-line return in the coming months [15].

Core Insights - The upcoming earnings report for Charles River Laboratories (CRL) is anticipated to show a quarterly earnings per share (EPS) of $2.33, reflecting a decline of 12.4% year-over-year [1] - Revenue is forecasted to be $985.92 million, indicating a decrease of 1.7% compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised 0.1% higher in the last 30 days, indicating a collective reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts project 'Revenue- Research Models and Services' to be $202.12 million, a decrease of 1% year-over-year [5] - The estimate for 'Revenue- Manufacturing Solutions' is $199.51 million, reflecting a year-over-year increase of 2.3% [5] - 'Revenue- Discovery and Safety Assessment' is expected to reach $585.53 million, indicating a decline of 3% from the previous year [5] Operating Income Estimates - 'Operating income- Research Models and Services- Non-GAAP' is expected to be $42.04 million, down from $46.54 million in the same quarter last year [6] - 'Operating income- Discovery and Safety Assessment- Non-GAAP' is projected at $142.16 million, compared to $148.98 million in the previous year [6] - 'Operating income- Manufacturing Solutions- Non-GAAP' is estimated to be $50.75 million, down from $55.91 million year-over-year [7] - The average prediction for 'Operating income- Research Models and Services' is $30.77 million, compared to $13.77 million in the same quarter last year [7] - 'Operating income- Discovery and Safety Assessment' is expected to reach $107.95 million, up from $62.86 million in the previous year [8] Stock Performance - Charles River shares have decreased by 26.6% in the past month, contrasting with the Zacks S&P 500 composite's decline of 1.7% [8] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [8]

Core Insights - Charles River Laboratories International, Inc. (CRL) is set to report its third-quarter 2025 results on November 5, with adjusted earnings per share (EPS) of $3.12 in the last quarter exceeding the Zacks Consensus Estimate by 24.80% [1] Q3 Estimates - The Zacks Consensus Estimate for CRL's revenues is $984.6 million, indicating a 2.5% decline from the previous year [2] - The Zacks Consensus Estimate for EPS is $2.32, reflecting a 10.4% year-over-year decrease [2] Estimate Revision Trend - Earnings estimates for CRL's third quarter have decreased by 1 cent in the past week [3] Factors Impacting Performance - **Research Models and Services (RMS)**: Expected revenue growth of 6.5% in Q3 2025, driven by strong sales in research model services and favorable pricing, particularly in the GEMS and Insourcing Solutions businesses [4][5] - **Discovery and Safety Assessment (DSA)**: Anticipated revenue decline of 7% due to budget pressures from biopharmaceutical clients and cash constraints faced by smaller biotech firms [6][8] - **Manufacturing Solutions**: Projected revenue drop of 0.6% in Q3 2025, influenced by geopolitical tensions and supply chain disruptions, although the Microbial Solutions business is expected to perform well [9][10] Earnings Whispers - CRL has an Earnings ESP of +0.61% and a Zacks Rank of 3, indicating a moderate chance of beating estimates [11]

Core Insights - Charles River Laboratories (CRL) reported revenue of $984.17 million for Q1 2025, reflecting a year-over-year decline of 2.7% but exceeding the Zacks Consensus Estimate by 5.25% [1] - The earnings per share (EPS) for the same quarter was $2.34, up from $2.27 a year ago, representing a surprise of 13.59% over the consensus estimate of $2.06 [1] Revenue Breakdown - Revenue from Research Models and Services was $213.07 million, surpassing the average estimate of $207.28 million, with a year-over-year change of -3.6% [4] - Revenue from Discovery and Safety Assessment reached $592.61 million, exceeding the average estimate of $545.81 million, with a year-over-year decline of -2.1% [4] - Revenue from Manufacturing Solutions was $178.49 million, slightly below the average estimate of $182.94 million, showing a year-over-year change of -3.6% [4] - Revenue from Services totaled $797.92 million, exceeding the average estimate of $755.46 million, with a year-over-year decline of -2.3% [4] - Revenue from Products was $186.25 million, above the average estimate of $178.87 million, reflecting a year-over-year change of -4.3% [4] Operating Income Analysis - Non-GAAP operating income for Research Models and Services was $57.73 million, exceeding the average estimate of $46.59 million [4] - Non-GAAP operating income for Discovery and Safety Assessment was $141.70 million, surpassing the average estimate of $122.57 million [4] - Non-GAAP operating income for Manufacturing Solutions was -$8.62 million, significantly below the average estimate of $41.50 million [4] - Unallocated Corporate Overhead reported an operating income of -$54.27 million, better than the average estimate of -$59.34 million [4] Stock Performance - Over the past month, shares of Charles River have returned -6.6%, contrasting with the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]